Research at Clarity DTX
Clarity DTX operates a portfolio of more than thirty condition-specific digital health apps, each built around a single diagnosis and the instruments that matter for it. Patients consent to use a consumer product. Researchers can engage with a de-identified, IRB-governed window into that real-world data when a protocol and consent path are in place.
This page is an orientation for principal investigators, pharma RWE teams, and instrument developers who are evaluating Clarity DTX as a source of patient-generated health data.
Why patient-generated data from condition-specific apps
Patients who open an app designed for their condition report more consistently than patients asked to use a generic wellness tracker. The onboarding is condition-aligned. The daily check-in surfaces the symptoms, biomarkers, and adherence events that matter for that diagnosis. The instruments are the validated ones for the field.
The practical result is a richer longitudinal record per consented subject, with less missingness on the variables a study actually cares about. For observational real-world evidence, digital endpoint validation, and ePRO arms of decentralised trials, that fidelity is the difference between a usable dataset and a noisy one.
Clarity DTX has invested in this portfolio approach specifically because horizontal trackers consistently under-perform on adherence for chronic-condition cohorts. The apps are free to patients; research access is a separate, consented, governed layer on top.
Condition-specific ePRO libraries already deployed
Each app ships with a core bundle of patient-reported outcome measures and structured capture surfaces matched to its condition. The bundle is the default daily experience for the patient, not a research overlay.
- Neurology — MS Tracker (relapse log, MFIS fatigue, mobility, cognition), Migraine Tracker (headache log, MIDAS, triggers), PTSD Tracker, Lyme Tracker.
- Psychiatry — BPD Tracker (DBT skills, self-harm flags, PHQ-9, GAD-7), Bipolar, Anxiety, Depression, ADHD, OCD.
- Metabolic and endocrine — GLP-1 Tracker (titration, weight, waist, GI side effects, glucose), Pepture (peptide dose adherence, site rotation, reconstitution, biomarkers), Diabetes, PCOS, Hashimoto (TSH, FT4, FT3, symptom cluster).
- Autoimmune and rheumatology — Lupus, Arthritis, Psoriasis, Eczema, MCAS.
- Women’s health and reproductive — IVF Tracker (injection log, scans, beta-hCG, outcomes), Endometriosis.
- Cardiopulmonary — AFib Tracker (episode log, HR and BP, anticoagulant adherence, EQ-5D), Hypertension, Asthma, COPD.
- Oncology and chronic — Cancer Tracker, Fibromyalgia, CFS Tracker.
- Sleep and other — Insomnia Tracker, EDS Tracker, HIV Tracker.
Study-specific instruments (PROMIS short forms, disease-specific PROs, custom scales) can be added alongside the condition’s default bundle, scheduled or trigger-based, without disrupting the consumer experience.
Clinical partnerships and IRB-friendly data access
Clarity DTX treats research consent as a distinct surface from consumer consent. A patient using the app has not agreed to be in research. Every study goes through its own IRB-reviewed consent flow presented inside the app to eligible users. Declining research leaves consumer use unchanged.
Researcher access is scoped to the variables the approved protocol defines. HIPAA Safe Harbor de-identification is applied by default. Identified access is available only where the protocol and explicit subject consent allow it. Subject withdrawal follows the rules the reviewing IRB approved.
- IRB of record — Clarity DTX works with your IRB or can recommend one.
- Separate consent surface — Shown in-app to eligible users only.
- Scope-limited access — Researchers see the fields the protocol defines, nothing broader.
- Audit trail — Every access event is logged and available to the IRB on request.
- No resale — Clarity DTX does not sell datasets to brokers. Research access is bilateral with a named partner.
- Publication rights — Retained by researchers per study agreement; Clarity DTX reviews for accuracy, not veto.
How researchers request de-identified cohorts
The usual path starts with a feasibility conversation under NDA. Clarity DTX shares bucketed cohort magnitudes by therapeutic area so investigators can shape a realistic study. Exact numbers and field-level availability are shared once scope is discussed.
From there, engagements fall into a handful of shapes: observational real-world evidence with longitudinal ePRO and adherence, instrument validation with paired classical and digital PRO captures, ePRO arms of decentralised trials with CDISC-aligned exports, and post-market surveillance cohorts for launched therapies. Each shape has a typical timeline from IRB approval to first data cut (four to six weeks for observational, eight to twelve for a DCT ePRO arm with build and validation).
De-identified exports are provided in CSV, SAS, or FHIR formats on the schedule the protocol specifies. Access is revocable at any time. Where Apple Health or Health Connect data is consented, sleep, activity, and vitals are available as study variables alongside the in-app captures.
What we do not do
Clarity DTX apps are not medical devices, do not provide diagnosis, and do not recommend doses. Research outputs describe what consented patients reported in real-world conditions. Interpretation for clinical decision-making is the responsibility of the reviewing investigators and their IRB.
Contact the research team
Send a brief note with your study aims, principal investigator, institution, and IRB status. A Clarity DTX research lead responds within two working days.